Spatio-Temporal Landscape of Whole-Genome DNA Methylation Patterns in Ovarian Cancer
Giovanni MarchiiD, Kari LavikkaiD, Yilin LiiD, Veli‐Matti IsoviitaiD, Giulia MicoliiD, Daria AfentevaiD, Elsi Pöllänen, Susanna HolmströmiD, Antti HäkkineniD, Elina ValkoneniD, Ilari Maarala, J. Astren, Chiara FacciottoiD, Felix DietleiniD, Sakari HietaneniD, Taru MuraneniD, Jaana OikkoneniD, Johanna HynnineniD, Anni VirtaneniD, Alexandra LahtineniD, Sampsa HautaniemiiD
Abstract
Understanding how epigenetic mechanisms shape metastatic dissemination and therapy response in ovarian high-grade serous carcinoma (HGSC) has been hindered by the absence of large, anatomically diverse, and longitudinal datasets. Here, we present a comprehensive resource of the HGSC methylome, comprising 404 whole-genome bisulfite sequenced samples from 125 patients belonging to the real-world DECIDER trial. Tumor-specific methylomes were integrated with matched RNA sequencing, whole-genome sequencing and clinical outcomes, which enabled identification of > 8,500 regulatory promoters. Our results show that the regulatory methylome is largely established early in tumor progression and remains stable through chemotherapy. Tumors with poor response to treatment are marked by widespread promoter hypermethylation, particularly cancer cells in ascites, leading to epigenetic silencing of pathways targeted by chemotherapy agents. Our proof-of-principle analysis shows that these epigenetic signatures are detected in plasma-derived DNA, highlighting the value of DNA methylation in liquid biopsy-based disease monitoring. This study provides a foundational resource for dissecting the spatial and temporal dynamics of cancer methylomes and establishes a framework for integrating epigenetic states with clinical trajectories in HGSC.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DNA methylation landscapes of matched primary and recurrent high grade serous ovarian cancers are preserved throughout disease progression and chemoresistance.
Nicole Gull, Michelle R. Jones, … Simon A. Gayther·bioRxiv·Aug 25, 2020
- Blood Based Biomarkers of DNA Methylation Associated with Platinum Resistance in High Grade Serous Ovarian Cancer
Elnaz Abbasi Farid, Shu Zhang, … Kenneth P. Nephew·bioRxiv·Apr 24, 2026
- Amplification of genomic regions harbouring genes with dose-limiting effects provides selection pressure for acquiring aberrant epigenetic silencing in ovarian cancer
N. Bonito, I. Eringyte, … E. Curry·bioRxiv·May 7, 2019
- Multi-modal characterization of transcriptional programs that drive metastatic cascades to solid sites and ascites in ovarian cancer
Kaiyang Zhang, Essi Kahelin, … Sampsa Hautaniemi·bioRxiv·Aug 26, 2025
- A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high grade serous ovarian cancer
P. Lo Riso, C. E. Villa, … G. Testa·bioRxiv·Nov 30, 2018
- Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection
Qiuning Yu, Namei Xia, … Xianping Lv·BMC Medical GenomicsPeer-reviewed·Nov 29, 2022